Cargando…
Mouse Invariant Monoclonal Antibody NKT14: A Novel Tool to Manipulate iNKT Cell Function In Vivo
Invariant Natural Killer T (iNKT) cells are a T cell subset expressing an invariant T Cell Receptor (TCR) that recognizes glycolipid antigens rather than peptides. The cells have both innate-like rapid cytokine release, and adaptive-like thymic positive selection. iNKT cell activation has been impli...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4608835/ https://www.ncbi.nlm.nih.gov/pubmed/26474487 http://dx.doi.org/10.1371/journal.pone.0140729 |
_version_ | 1782395728822272000 |
---|---|
author | Scheuplein, Felix Lamont, Deanna J. Poynter, Matthew E. Boyson, Jonathan E. Serreze, David Lundblad, Lennart K. A. Mashal, Robert Schaub, Robert |
author_facet | Scheuplein, Felix Lamont, Deanna J. Poynter, Matthew E. Boyson, Jonathan E. Serreze, David Lundblad, Lennart K. A. Mashal, Robert Schaub, Robert |
author_sort | Scheuplein, Felix |
collection | PubMed |
description | Invariant Natural Killer T (iNKT) cells are a T cell subset expressing an invariant T Cell Receptor (TCR) that recognizes glycolipid antigens rather than peptides. The cells have both innate-like rapid cytokine release, and adaptive-like thymic positive selection. iNKT cell activation has been implicated in the pathogenesis of allergic asthma and inflammatory diseases, while reduced iNKT cell activation promotes infectious disease, cancer and certain autoimmune diseases such as Type 1 diabetes (T1D). Therapeutic means to reduce or deplete iNKT cells could treat inflammatory diseases, while approaches to promote their activation may have potential in certain infectious diseases, cancer or autoimmunity. Thus, we developed invariant TCR-specific monoclonal antibodies to better understand the role of iNKT cells in disease. We report here the first monoclonal antibodies specific for the mouse invariant TCR that by modifying the Fc construct can specifically deplete or activate iNKT cells in vivo in otherwise fully immuno-competent animals. We have used both the depleting and activating version of the antibody in the NOD model of T1D. As demonstrated previously using genetically iNKT cell deficient NOD mice, and in studies of glycolipid antigen activated iNKT cells in standard NOD mice, we found that antibody mediated depletion or activation of iNKT cells respectively accelerated and retarded T1D onset. In BALB/c mice, ovalbumin (OVA) mediated airway hyper-reactivity (AHR) was abrogated with iNKT cell depletion prior to OVA sensitization, confirming studies in knockout mice. Depletion of iNKT cells after sensitization had no effect on AHR in the conducting airways but did reduce AHR in the lung periphery. This result raises caution in the interpretation of studies that use animals that are genetically iNKT cell deficient from birth. These activating and depleting antibodies provide a novel tool to assess the therapeutic potential of iNKT cell manipulation. |
format | Online Article Text |
id | pubmed-4608835 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-46088352015-10-29 Mouse Invariant Monoclonal Antibody NKT14: A Novel Tool to Manipulate iNKT Cell Function In Vivo Scheuplein, Felix Lamont, Deanna J. Poynter, Matthew E. Boyson, Jonathan E. Serreze, David Lundblad, Lennart K. A. Mashal, Robert Schaub, Robert PLoS One Research Article Invariant Natural Killer T (iNKT) cells are a T cell subset expressing an invariant T Cell Receptor (TCR) that recognizes glycolipid antigens rather than peptides. The cells have both innate-like rapid cytokine release, and adaptive-like thymic positive selection. iNKT cell activation has been implicated in the pathogenesis of allergic asthma and inflammatory diseases, while reduced iNKT cell activation promotes infectious disease, cancer and certain autoimmune diseases such as Type 1 diabetes (T1D). Therapeutic means to reduce or deplete iNKT cells could treat inflammatory diseases, while approaches to promote their activation may have potential in certain infectious diseases, cancer or autoimmunity. Thus, we developed invariant TCR-specific monoclonal antibodies to better understand the role of iNKT cells in disease. We report here the first monoclonal antibodies specific for the mouse invariant TCR that by modifying the Fc construct can specifically deplete or activate iNKT cells in vivo in otherwise fully immuno-competent animals. We have used both the depleting and activating version of the antibody in the NOD model of T1D. As demonstrated previously using genetically iNKT cell deficient NOD mice, and in studies of glycolipid antigen activated iNKT cells in standard NOD mice, we found that antibody mediated depletion or activation of iNKT cells respectively accelerated and retarded T1D onset. In BALB/c mice, ovalbumin (OVA) mediated airway hyper-reactivity (AHR) was abrogated with iNKT cell depletion prior to OVA sensitization, confirming studies in knockout mice. Depletion of iNKT cells after sensitization had no effect on AHR in the conducting airways but did reduce AHR in the lung periphery. This result raises caution in the interpretation of studies that use animals that are genetically iNKT cell deficient from birth. These activating and depleting antibodies provide a novel tool to assess the therapeutic potential of iNKT cell manipulation. Public Library of Science 2015-10-16 /pmc/articles/PMC4608835/ /pubmed/26474487 http://dx.doi.org/10.1371/journal.pone.0140729 Text en © 2015 Scheuplein et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Scheuplein, Felix Lamont, Deanna J. Poynter, Matthew E. Boyson, Jonathan E. Serreze, David Lundblad, Lennart K. A. Mashal, Robert Schaub, Robert Mouse Invariant Monoclonal Antibody NKT14: A Novel Tool to Manipulate iNKT Cell Function In Vivo |
title | Mouse Invariant Monoclonal Antibody NKT14: A Novel Tool to Manipulate iNKT Cell Function In Vivo
|
title_full | Mouse Invariant Monoclonal Antibody NKT14: A Novel Tool to Manipulate iNKT Cell Function In Vivo
|
title_fullStr | Mouse Invariant Monoclonal Antibody NKT14: A Novel Tool to Manipulate iNKT Cell Function In Vivo
|
title_full_unstemmed | Mouse Invariant Monoclonal Antibody NKT14: A Novel Tool to Manipulate iNKT Cell Function In Vivo
|
title_short | Mouse Invariant Monoclonal Antibody NKT14: A Novel Tool to Manipulate iNKT Cell Function In Vivo
|
title_sort | mouse invariant monoclonal antibody nkt14: a novel tool to manipulate inkt cell function in vivo |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4608835/ https://www.ncbi.nlm.nih.gov/pubmed/26474487 http://dx.doi.org/10.1371/journal.pone.0140729 |
work_keys_str_mv | AT scheupleinfelix mouseinvariantmonoclonalantibodynkt14anoveltooltomanipulateinktcellfunctioninvivo AT lamontdeannaj mouseinvariantmonoclonalantibodynkt14anoveltooltomanipulateinktcellfunctioninvivo AT poyntermatthewe mouseinvariantmonoclonalantibodynkt14anoveltooltomanipulateinktcellfunctioninvivo AT boysonjonathane mouseinvariantmonoclonalantibodynkt14anoveltooltomanipulateinktcellfunctioninvivo AT serrezedavid mouseinvariantmonoclonalantibodynkt14anoveltooltomanipulateinktcellfunctioninvivo AT lundbladlennartka mouseinvariantmonoclonalantibodynkt14anoveltooltomanipulateinktcellfunctioninvivo AT mashalrobert mouseinvariantmonoclonalantibodynkt14anoveltooltomanipulateinktcellfunctioninvivo AT schaubrobert mouseinvariantmonoclonalantibodynkt14anoveltooltomanipulateinktcellfunctioninvivo |